RxDoctor Payments Data

Melissa Heiry

Neurology · Philadelphia, PANPI 1851734255

Payments from drug & device makers

$37,621in general payments, 2019–2025

Across 54 payments — averaging $696.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$33K
  • Medtronic$2K
  • Abbott$1K
  • Amneal Pharmaceuticals LLC$1K
  • Boston Scientific$753
  • Teva Pharmaceuticals USA, Inc.$100
  • plus $123 from 3 others

What the payments were for

  • Consulting fees$3,04842%
  • Grants$1,56322%
  • Food & beverage$2,59336%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,621 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$48,439
Medicare patients
183
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate29$210,730
AustedoDeutetrabenazine25$152,026
GocovriAmantadine Hcl35$148,462
RytaryCarbidopa/Levodopa70$126,031
NourianzIstradefylline20$36,990
Carbidopa-LevodopaCarbidopa/Levodopa453$26,192
NeuproRotigotine16$17,650
MyrbetriqMirabegron12$15,696
Carbidopa57$15,471
Carbidopa-Levodopa ErCarbidopa/Levodopa305$12,555
Rasagiline Mesylate63$9,140
Entacapone31$8,052
AmantadineAmantadine Hcl66$6,934
Ropinirole ErRopinirole Hcl17$6,462
Rivastigmine21$5,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$29$210,73029 claims
Teva Pharmaceuticals USA, Inc.Austedo$100$152,02625 claims
Amneal Pharmaceuticals LLCRytary$1,058$126,03170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →